Sarepta Therapeutics’ Post

What’s behind the workforce gap in the cell and gene therapy sector? Simply put, the number of companies and clinical trial programs has grown so fast that the sector needs more talent to keep pace. Read our latest Sector Snapshot to dive into the issue: https://lnkd.in/ep2DZ65M #cellandgenetherapy #workforcedevelopment

Interested to learn about the role of AAVs in gene therapy, how to manufacture AAVs, and moving from discovery to clinical and commercial manufacturing? Download our eBook to read about the considerations for your gene therapy manufacturing strategy!

Interested to learn about the role of AAVs in gene therapy, how to manufacture AAVs, and moving from discovery to clinical and commercial manufacturing? Download our eBook to read about the considerations for your gene therapy manufacturing strategy!

The latest headlines in "IntellaTurn's Weekly Scoop" include: Latest FDA approvals | Billion dollar headlines | Upcoming cell and gene therapy decisions | Inside Novo Nordisk | and more. Read it all at https://lnkd.in/gT-zZn7S.

Have you heard of gene therapies? In this series of the 2024 Future Forecast, learn about the significance of gene therapies, and how employers can navigate the high costs associated with these treatments.

Check out our latest show reel to learn more about Pharmaron’s comprehensive analytical support and how we can help you with your next gene therapy CMC project.

The latest report from ARM presents an astonishing snapshot of the cell and gene therapy sector. It is both validating and somewhat concerning to witness such high momentum in this field without the necessary infrastructure to support it. The industry has reached a pivotal stage where boundaries are being pushed, but there is still an important conversation missing – the need for standardized, consistent, and high-quality starting materials, starting with #cellcollections from patients or donors. The principle of "quality in, quality out" holds true here; beginning the process with efficiency leads to stronger efficiencies downstream. Really excited to work at #TerumoBloodandCellTechnologies where we are recognizing our value within this #cellandgenetherapy industry by our ability to help provide efficient, standardized, and consistent collections that contribute to enabling these therapies in developing. Additionally, we are also acknowledging and helping fill several key areas that are currently lacking but crucial for accommodating this growing momentum - such as training programs expertise in data analytics and data management. Collaboration is essential as we move forward together at all stages of the cell therapy manufacturing process. By leveraging our collective knowledge and resources, we can continue approaching cell therapies with a comprehensive approach. To learn more about these findings you can read the full report:

Looking to know what's trending in the cell and gene therapy sector? 🧬📈 Dive into our newly released Q2 2023 data report to view sector highlights in clinical trials, investment, and developer growth. Access the full data here: https://lnkd.in/ebJw3Kxi

Are you wondering if fast-tracking in vivo testing for cell and gene therapies is the most efficient strategy? Gain insights from experts in research, manufacturing, and testing to navigate the gene therapy development journey. Watch the webinar here: https://okt.to/PauwNK #cellandgenetherapy #aavgenetherapy

Interested to learn about the role of AAVs in gene therapy, how to manufacture AAVs, and moving from discovery to clinical and commercial manufacturing? Download our eBook to read about the considerations for your gene therapy manufacturing strategy!